Much has been written in recent months regarding the growing use of artificial intelligence (AI) in medicine and the potential benefits and risks of its use. A new generation of AI technologies, ChatGPT, is driven by advances in large language models. ChatGPT reached 100 million users within 64 days of its release on November 30, 2022, and it has shown the ability to write text on a wide range of topics. An article in this issue by Drs Jose de Leon and Carlos De Las Cuevas brings the issues regarding use of ChatGPT to clinical psychopharmacology and to this journal. It also provides an opportunity for me to review for the readership the polices of the Journal of Clinical Psychopharmacology (JCP) regarding the use of AI by authors and reviewers.